Cargando…

Experiences in Engaging the Public on Biotechnology Advances and Regulation

Public input is often sought as part of the biosafety decision-making process. Information and communication about the advances in biotechnology are part of the first step to engagement. This step often relies on the developers and introducers of the particular innovation, for example, an industry-f...

Descripción completa

Detalles Bibliográficos
Autores principales: Quinlan, M. Megan, Smith, Joe, Layton, Raymond, Keese, Paul, Agbagala, Ma. Lorelie U., Palacpac, Merle B., Ball, Louise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735352/
https://www.ncbi.nlm.nih.gov/pubmed/26870726
http://dx.doi.org/10.3389/fbioe.2016.00003
_version_ 1782413066214834176
author Quinlan, M. Megan
Smith, Joe
Layton, Raymond
Keese, Paul
Agbagala, Ma. Lorelie U.
Palacpac, Merle B.
Ball, Louise
author_facet Quinlan, M. Megan
Smith, Joe
Layton, Raymond
Keese, Paul
Agbagala, Ma. Lorelie U.
Palacpac, Merle B.
Ball, Louise
author_sort Quinlan, M. Megan
collection PubMed
description Public input is often sought as part of the biosafety decision-making process. Information and communication about the advances in biotechnology are part of the first step to engagement. This step often relies on the developers and introducers of the particular innovation, for example, an industry-funded website has hosted various authorities to respond to questions from the public. Alternative approaches to providing information have evolved, as demonstrated in sub-Saharan Africa where non-governmental organizations and associations play this role in some countries and subregions. Often times, those in the public who choose to participate in engagement opportunities have opinions about the overall biosafety decision process. Case-by-case decisions are made within defined regulatory frameworks, however, and in general, regulatory consultation does not provide the opportunity for input to the overall decision-making process. The various objectives on both sides of engagement can make the experience challenging; there are no clear metrics for success. The situation is challenging because public input occurs within the context of the local legislative framework, regulatory requirements, and the peculiarities of the fairly recent biosafety frameworks, as well as of public opinion and individual values. Public engagement may be conducted voluntarily, or may be driven by legislation. What can be taken into account by the decision makers, and therefore what will be gathered and the timing of consultation, also may be legally defined. Several practical experiences suggest practices for effective engagement within the confines of regulatory mandates: (1) utilizing a range of resources to facilitate public education and opportunities for understanding complex technologies; (2) defining in advance the goal of seeking input; (3) identifying and communicating with the critical public groups from which input is needed; (4) using a clearly defined approach to gathering and assessing what will be used in making the biosafety decision; and (5) communicating using clear and simple language. These practices create a foundation for systematic methods to gather, acknowledge, respond to, and even incorporate public input. Applying such best practices will increase transparency and optimize the value of input from the public.
format Online
Article
Text
id pubmed-4735352
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-47353522016-02-11 Experiences in Engaging the Public on Biotechnology Advances and Regulation Quinlan, M. Megan Smith, Joe Layton, Raymond Keese, Paul Agbagala, Ma. Lorelie U. Palacpac, Merle B. Ball, Louise Front Bioeng Biotechnol Bioengineering and Biotechnology Public input is often sought as part of the biosafety decision-making process. Information and communication about the advances in biotechnology are part of the first step to engagement. This step often relies on the developers and introducers of the particular innovation, for example, an industry-funded website has hosted various authorities to respond to questions from the public. Alternative approaches to providing information have evolved, as demonstrated in sub-Saharan Africa where non-governmental organizations and associations play this role in some countries and subregions. Often times, those in the public who choose to participate in engagement opportunities have opinions about the overall biosafety decision process. Case-by-case decisions are made within defined regulatory frameworks, however, and in general, regulatory consultation does not provide the opportunity for input to the overall decision-making process. The various objectives on both sides of engagement can make the experience challenging; there are no clear metrics for success. The situation is challenging because public input occurs within the context of the local legislative framework, regulatory requirements, and the peculiarities of the fairly recent biosafety frameworks, as well as of public opinion and individual values. Public engagement may be conducted voluntarily, or may be driven by legislation. What can be taken into account by the decision makers, and therefore what will be gathered and the timing of consultation, also may be legally defined. Several practical experiences suggest practices for effective engagement within the confines of regulatory mandates: (1) utilizing a range of resources to facilitate public education and opportunities for understanding complex technologies; (2) defining in advance the goal of seeking input; (3) identifying and communicating with the critical public groups from which input is needed; (4) using a clearly defined approach to gathering and assessing what will be used in making the biosafety decision; and (5) communicating using clear and simple language. These practices create a foundation for systematic methods to gather, acknowledge, respond to, and even incorporate public input. Applying such best practices will increase transparency and optimize the value of input from the public. Frontiers Media S.A. 2016-02-02 /pmc/articles/PMC4735352/ /pubmed/26870726 http://dx.doi.org/10.3389/fbioe.2016.00003 Text en Copyright © 2016 Quinlan, Smith, Layton, Keese, Agbagala, Palacpac and Ball. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Quinlan, M. Megan
Smith, Joe
Layton, Raymond
Keese, Paul
Agbagala, Ma. Lorelie U.
Palacpac, Merle B.
Ball, Louise
Experiences in Engaging the Public on Biotechnology Advances and Regulation
title Experiences in Engaging the Public on Biotechnology Advances and Regulation
title_full Experiences in Engaging the Public on Biotechnology Advances and Regulation
title_fullStr Experiences in Engaging the Public on Biotechnology Advances and Regulation
title_full_unstemmed Experiences in Engaging the Public on Biotechnology Advances and Regulation
title_short Experiences in Engaging the Public on Biotechnology Advances and Regulation
title_sort experiences in engaging the public on biotechnology advances and regulation
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735352/
https://www.ncbi.nlm.nih.gov/pubmed/26870726
http://dx.doi.org/10.3389/fbioe.2016.00003
work_keys_str_mv AT quinlanmmegan experiencesinengagingthepubliconbiotechnologyadvancesandregulation
AT smithjoe experiencesinengagingthepubliconbiotechnologyadvancesandregulation
AT laytonraymond experiencesinengagingthepubliconbiotechnologyadvancesandregulation
AT keesepaul experiencesinengagingthepubliconbiotechnologyadvancesandregulation
AT agbagalamalorelieu experiencesinengagingthepubliconbiotechnologyadvancesandregulation
AT palacpacmerleb experiencesinengagingthepubliconbiotechnologyadvancesandregulation
AT balllouise experiencesinengagingthepubliconbiotechnologyadvancesandregulation